The TGA has approved Vertex's TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosisaged two to five who have at least one F508del mutation in the CF transmembrane conductance regulator gene. …
TGA extends approval for Vertex's cystic fibrosis therapy ahead of PBAC consideration
February 8, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Week in Review' Podcast - 26 July
July 26, 2024 - - Podcast -
'We approached stakeholders that were highly engaged with the HTA review process'
July 26, 2024 - - Latest News -
Preaching transparency and not practising it is the worst possible look
July 26, 2024 - - Latest News -
Cartherics announces new licensing agreement for innovative cardiac cell therapy
July 25, 2024 - - Latest News -
New large study shows vaccination halves the risk of patients suffering Long-COVID
July 25, 2024 - - Latest News -
These layered levels of privilege are not making decision-making or the system better
July 25, 2024 - - Latest News -
Telix completes significant raise that could be used for acquisitions
July 25, 2024 - - Latest News